Effects of different mesenchymal stromal cell sources and delivery routes in experimental emphysema

Area of Science:

• Regenerative Medicine
• Pulmonary Medicine
• Cell Therapy

Background:

• Emphysema is a chronic lung disease characterized by alveolar destruction and inflammation.
• Mesenchymal stromal cells (MSCs) show therapeutic potential for lung diseases.
• The impact of MSC source and administration route on emphysema treatment is not fully understood.

Purpose of the Study:

• To investigate the effects of different MSC sources (bone marrow, adipose tissue, lung) and administration routes (intravenous, intratracheal) on lung inflammation and remodeling in a mouse model of emphysema.
• To compare the efficacy of various MSC interventions in mitigating lung damage and improving lung function.

Main Methods:

• Experimental emphysema was induced in C57BL/6 mice using porcine pancreatic elastase.
• Mesenchymal stromal cells (MSCs) from bone marrow (BM), adipose tissue (AD), or lung (L) were administered intravenously (IV) or intratracheally (IT).
• Lung tissue and cardiovascular function were assessed one week after MSC administration.

Main Results:

• All tested MSCs, regardless of source or route, reduced lung inflammation, apoptosis, and damage, while increasing elastic fiber content.
• Intratracheal administration further reduced alveolar hyperinflation and collagen deposition compared to intravenous.
• Intravenous administration of BM- and AD-MSCs decreased M1 macrophages and pulmonary hypertension, and increased vascular endothelial growth factor.
• Bone marrow-derived MSCs administered intravenously showed a greater increase in M2 macrophages compared to intratracheal administration.

Conclusions:

• Different MSC sources and administration routes variably ameliorate elastase-induced lung damage.
• Intravenous administration of bone marrow-derived MSCs demonstrates superior effects on cardiovascular function and macrophage polarization towards an M2 phenotype.